What is Atopic Dermatitis
Atopic dermatitis (AD) is a skin disease that causes a lot of itching, inflammation, and skin barrier problems. It affects about 3-10% of adults and 20% of children worldwide. The first symptoms usually develop during childhood, and about 50% of cases are diagnosed in the first year of life.
Atopic dermatitis can reduce the quality of life for patients and their families. In addition, patients with atopic dermatitis are more likely to have other atopic disorders like asthma, allergic rhinitis, and chronic sinusitis.
Using Topical Corticosteroids for Treatment of AD
Topical corticosteroids are the primary treatment for mild to moderate Atopic dermatitis. If someone has moderate to severe Atopic dermatitis, they will need to use topical corticosteroids for a long time. However, there is not much data on how effective this works for kids. In severe Atopic dermatitis cases that do not get better with topical corticosteroids, doctors might give the person a short course of systemic therapy with immunosuppressants.
A recent analysis of gut microbiota of patients with Atopic dermatitis has shown a reduced amount of Faecalibacterium prausnitzii, an anti-inflammatory bacteria. Probiotics may help recover the gut microbiota and as potential nutritional supplements in Atopic dermatitis treatment.
The foremost aim of this study was to see if a mixture of probiotics can be an effective and safe coadjuvant treatment to reduce the SCORAD (Scoring Atopic Dermatitis) index and the number of days children needed topical steroid treatment during moderate AD flares.
The Study Method On Using Probiotics for AD
50 participants in a study were children aged 4 to 17 years old with moderate atopic dermatitis. They had not used immunosuppressive drugs in the previous three months or antibiotics in the last two weeks. They also did not have a concurrent intestinal bowel disease or signs of bacterial infection.
The children were randomly placed into two groups: one group of 26 participants received probiotics while the other, a placebo.
Examiners gave the Test Group a daily capsule containing freeze-dried powder with 109 total colony-forming units of the probiotic strains Bifidobacterium lactis CECT 8145, B longum CECT 7347, and Lactobacillus casei CECT 9104, with maltodextrin as a carrier for 12 weeks. The Control Group received a placebo (maltodextrin-only capsules).
No relevant adverse events were related to drug or placebo intake.
The children who took the probiotic had a 19.2 point reduction in their SCORAD index, which measures how bad their eczema is. This reduction was greater than in the children who did not take the probiotic.
This finding means that 83% of the children who took the probiotic had improvement in their eczema, while only 24% of the children who did not take the probiotic had improvement. Additionally, we found a significant reduction in the use of topical steroids to treat flares in the Probiotic Group compared to the Control Group.
The mixture of probiotics effectively reduced the SCORAD index and the use of topical steroids in patients with moderate Atopic dermatitis.